The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Antonino Capizzi; Michela Silvestri; Andrea Orsi; Renato Cutrera; Giovanni A. Rossi; Oliviero Sacco

doi:10.1186/s13052-017-0390-8

Italian Journal of Pediatrics (Aug 2017)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Antonino Capizzi,
Michela Silvestri,
Andrea Orsi,
Renato Cutrera,
Giovanni A. Rossi,
Oliviero Sacco

Affiliations

Antonino Capizzi: Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini
Michela Silvestri: Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini
Andrea Orsi: Department of Health Sciences, Hygiene Unit, IRCCS University Hospital San Martino Polyclinic
Renato Cutrera: Pediatric Pulmonology and Sleep & Long Term Ventilation Unit, Pediatric Hospital “Bambino Gesù”
Giovanni A. Rossi: Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini
Oliviero Sacco: Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini

DOI: https://doi.org/10.1186/s13052-017-0390-8
Journal volume & issue: Vol. 43, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the = 29 wGA subpopulation when specific risk factors are present.

Published in Italian Journal of Pediatrics

ISSN: 1720-8424 (Print); 1824-7288 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Pediatrics
Website: https://ijponline.biomedcentral.com/

About the journal

Abstract

Keywords